Payment overview · 2025
General Payments
$248.73
15 reported records · 7 companies
Healthcare provider profile · identity verified
Ahmed A Khalafallah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOLINE, IL · NPI 1366412934
Verified facts
What the public records show
CMS Open Payments records show Ahmed A Khalafallah, MD received $248.73 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.82 | 26.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.47 | 21.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.53 | 15.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.17 | 14.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.92 | 9.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.37 | 8.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.45 | 5.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.73 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.54 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.53 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.45 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 149 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 150 |
| Simvastatin | Simvastatin | 513 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 118 |
| Alprazolam | Alprazolam | 423 | 84 |
| Potassium Chloride | Potassium Chloride | 284 | 88 |
| Lisinopril | Lisinopril | 267 | 68 |
| Metformin Hcl | Metformin Hcl | 262 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 58 |
| Glimepiride | Glimepiride | 223 | 63 |
| Furosemide | Furosemide | 216 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 52 |
| Omeprazole | Omeprazole | 200 | 54 |
| Gabapentin | Gabapentin | 187 | 50 |
| Losartan Potassium | Losartan Potassium | 185 | 49 |
| Eliquis | Apixaban | 149 | 21 |
| Sertraline Hcl | Sertraline Hcl | 148 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 42 |
| Donepezil Hcl | Donepezil Hcl | 141 | 27 |
| Allopurinol | Allopurinol | 138 | 35 |
| Methylprednisolone | Methylprednisolone | 120 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 27 |
| Celecoxib | Celecoxib | 103 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 32 |
| Azithromycin | Azithromycin | 93 | 73 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 23 |
| Glipizide | Glipizide | 90 | 25 |
| Topiramate | Topiramate | 90 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 37 |
| Tramadol Hcl | Tramadol Hcl | 84 | 23 |
| Levetiracetam | Levetiracetam | 77 | suppressed |
| Nifedipine Er | Nifedipine | 77 | 20 |
| Ezetimibe | Ezetimibe | 67 | 20 |
| Atenolol | Atenolol | 65 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 18 |
| Memantine Hcl | Memantine Hcl | 60 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | suppressed |
| Spironolactone | Spironolactone | 55 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 55 | 11 |
| Jardiance | Empagliflozin | 53 | 18 |
| Trazodone Hcl | Trazodone Hcl | 51 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 15 |
| Carvedilol | Carvedilol | 46 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 34 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Ibuprofen | Ibuprofen | 39 | 15 |
| Montelukast Sodium | Montelukast Sodium | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 18 |
| Roflumilast | Roflumilast | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 14 |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.73 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, EVENITY, FARXIGA, KISUNLA, MOUNJARO, NURTEC ODT, OFEV, Ozempic, VOQUEZNA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error